Drug Trial Radar · NCT06908993
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
133
Planned (sponsor's estimate)
Start
Dec 9, 2025
Primary completion
Mar 15, 2028
Study completion Jul 15, 2028
Sponsor
- Lead sponsor
- Intergroupe Francophone de Cancerologie ThoraciqueAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The hypothesize is that tepotinib is more effective than the investigator's choice of treatment in patients with MET-mutated NSCLC who have progressed after at least one first-line treatment. The main benefit concerns patient access to tepotinib. There is currently no access to a new-generation MET TKI in France for METex14 patients, due to lack of comparative data. There are no phase III RCTs underway anywhere in the world. This study is the only opportunity, perhaps the last, to generate comparative data which, if positive, will enable the drug to be reimbursed. With this in mind, the methodology of this study was discussed with the HAS on several occasions beforehand, to ensure that it met their expectations. With a response rate of around 50% and a median progression-free survival of 11 months in previously-treated subjects based on clinical trials data, tepotinib is a key drug for METex14 NSCLC patients, who are generally elderly and frail, and for whom therapeutic options are limited. The investigators expect to observe a benefit for patients treated with tepotinib compared to the control arm in terms of PFS, quality of life, objective response rate and duration of response. The overall survival benefit may be compromised by allowing patients in the control arm to cross over to tepotinib once they have progressed. However, the investigators have decided to maintain this crossover and consequently use PFS as the primary endpoint, as there is no clinical equipoise regarding the efficacy of tepotinib in METex14 NSCLC patients. The EMA has already approved tepotinib based on efficacy and safety data from clinical trials, and patients and investigators already consider this treatment as an important therapeutic option. Indeed, both ESMO and ASCO guidelines recommend the use of MET TKIs in these patients. In France, although neither tepotinib nor capmatinib are available, crizotinib, a multi-target TKI also active on MET, can be used off-label. If cross-over to tepotinib was not allowed in this trial, most patients would still benefit from cross-over to a MET TKI by receiving off-label crizotinib, which would in any case lead to a misinterpretation of the OS data. Therefore, the investigators believe it is preferable to control for cross-over and expose progressive patients in the control arm to tepotinib and use PFS as the primary endpoint. Toxicity of MET TKIs is considered as manageable. In the VISION trial, of 313 patients treated with tepotinib (median age: 72 years), 109 (34.8%) experienced grade ≥3 treatment-related adverse events, leading to discontinuation in 46 patients (14.7%). Rates of adverse events (AE) were broadly consistent irrespective of prior therapies. Edema, the most common adverse event of clinical interest (AECI), was reported in 67.1% (grade ≥ 3, 11.2%). Median time to first edema onset was 7.9 weeks (range: 0.1-58.3). Edema was manageable with supportive measures, dose reduction (18.8%), and/or treatment interruption (23.1%), and rarely prompted discontinuation (4.3%). Other AECIs were also manageable and predominantly mild/moderate: hypoalbuminemia, 23.6% (grade ≥ 3, 3.5%); creatinine increase, 22.0% (grade ≥ 3, 1.0%); nausea, 23.3% (grade ≥ 3, 0.6%), diarrhea, 22.4% (grade ≥ 3, 0.3%), decreased appetite (grade ≥ 3, 0.3%), and ALT increase, 14.1% (grade ≥ 3, 2.2%). GI AEs typically occurred early and resolved in the first weeks10,13. Given the efficacy of tepotinib, the manageable safety profile, and the oral administration of tepotinib, the investigators anticipate that treatment with tepotinib will be associated with improved quality of life. Treatments offered in the control group correspond to standard treatments for advanced NSCLC in second line or beyond. In terms of prior lines of treatment, the eligibility criteria of the trial are aligned with the EMA label of tepotinib: "indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to MET gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy". The investigators have not included platinum-based chemotherapy as a treatment option in the control arm, considering that patients who are eligible to platinum-based chemotherapy should have received this regimen in first-line, as per ESMO guidelines14. Given the low efficacy of immunotherapy in patients with oncogene addiction, it is unlikely that some patients would receive immunotherapy alone as first-line treatment. Thus, the absence of platinum-based chemotherapy as a treatment choice in the control arm seems reasonable and will reduce the heterogeneity of this arm.
Conditions
- Advanced Non Small Cell Lung Cancer
- MET Exon 14 Mutation
Interventions
TepotinibDrug
Tepotinib will be given orally once daily at the dose of 500mg of tepotinib hydrochloride hydrate.
Pemetrexed (Alimta)Drug
500 mg/m² every 3 weeks
VinorelbineDrug
25-30 mg/m² D1, D8, every 3 weeks
Gemcitabine aloneDrug
1250 mg/m² D1, D8, every 3 weeks
DocetaxelDrug
75 mg/m² every 3 weeks
PaclitaxelDrug
90 mg/m² D1, D8, D15 every 4 weeks If bevacizumab added: 10 mg/kg D1, D15 every 4 weeks
PembrolizumabDrug
200 mg every 3 weeks
NivolumabDrug
240 mg every 2 weeks
AtezolizumabDrug
1200 mg every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: About 36 months
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Besançon - CHU
Besançon, France · Recruiting
Bordeaux - Institut Bergonie
Bordeaux, France · Recruiting
Brest - CHU
Brest, France · Recruiting
Caen - CRLCC
Caen, France · Recruiting
Centre Hospitalier Intercommunal de Créteil
Créteil, France · Recruiting
Dijon - Centre Georges-François Leclerc
Dijon, France · Recruiting
Grenoble - CHU
Grenoble, France · Recruiting
CHD Vendée
La Roche-sur-Yon, France · Recruiting
Le Mans - CHG
Le Mans, France · Recruiting
CHRU de Lille
Lille, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Institut Paoli Calmette
Marseille, France · Recruiting
Marseille - APHM
Marseille, France · Recruiting
Montpellier - CHU
Montpellier, France · Recruiting
Centre Antoine Lacassagne
Nice, France · Recruiting
AP-HP Hôpital Cochin
Paris, France · Recruiting
AP-HP Hôpital Tenon
Paris, France · Recruiting
Paris - APHP Bichat
Paris, France · Recruiting
Centre Hospitalier Général - Pau
Pau, France · Recruiting
Bordeaux - CHU
Pessac, France · Recruiting
Institut de Cancérologie de l'Ouest - René Gauducheau
Saint-Herblain, France · Recruiting
Sens - CH
Sens, France · Recruiting
Strasbourg - NHC
Strasbourg, France · Recruiting
Toulon - CHI
Toulon, France · Recruiting
CHU Toulouse
Toulouse, France · Recruiting
CHRU de Tours
Tours, France · Recruiting
CH de Valence
Valence, France · Recruiting
Nancy - CHU
Vandœuvre-lès-Nancy, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.